Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Alnylam Pharmaceuticals; AnaCardio AB; Applied Therapeutics; AstraZenca; Bayer AG; Biopeutics; Boehringer Ingelheim; Boston Scientific Corporation; Bristol-Myers Squibb; Corteria; CPC Clinical Research; Eli Lilly; Impluse Dynamics; Intellia Therapeutics; Ionis Pharmaceuticals; Janssen Pharmaceuticals; Medscape/WebMD; Merck/Schering Plough; Novartis; Quidel Corporation; Radcliffe Group
• Consultant and Research Support - Roche
• Consultant, co-founder and Non-executive director - Us2.ai
• Constultant and Reseach Support - Novo Nordisk